In an expansion on their previously announced alliance, Biocon Biologics will begin manufacturing a private-label version of insulin glargine for Civica, which Civica will then commercialize in the US. Biocon will continue to market its own brand of insulin glargine biosimilar (Semglee/insulin glargine-yfgn). Civica is a nonprofit pharmaceutical company, that was founded to expand access … Continue reading Biocon Will Produce an Insulin Glargine Biosimilar for Civica